Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof

US7592461B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Jingwu Duan · Yardley, US
• Bin Jiang · Norristown, US

Key dates

• Filing date: Dec 20, 2006
• Grant date: Sep 22, 2009
• Expiry date: Jan 17, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D285/08
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I):or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is -A1QA2-; Q is a bond, —C(═O)—, —OC(O)—, —C(═O)NR5—, —SOp—, —SOpNR5—, —C(O)O—, —NR5C(O)—, —OC(O)NR5—, —NR5C(O)O—, —S(O)pNR5C(O)—, —C(O)NR5S(O)p— —NR5S(O)p—, or —NR5C(═O)NR6—. Y is selected from hydrogen, C1-6alkyl, OR16, substituted C1-6alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A1 and A2 are independently selected from a bond, C1-3alkylene, or C1-3alkenylene, and R1-R11 are defined herein. Also provided are pharmaceutical compositions, combinations, and methods of treating obesity, diabetes and inflammatory- or immune-associated diseases comprising said compounds.